Is AADI or MRK a better dividend investment in 2026?

AADI currently yields 97.56% with a 5% 5-year dividend growth rate. MRK yields 3.25% with 8.2% growth. The better choice depends on your goal: AADI offers higher current income.

What is the dividend yield difference between AADI and MRK?

AADI has a forward dividend yield of 97.56% ($2.00/share annually). MRK yields 3.25% ($3.08/share annually). The yield gap is 94.31 percentage points.

Home › Compare › AADI vs MRK

AADI vs MRK: Dividend Comparison 2026

AADI yields 97.56% · MRK yields 3.25%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AADI wins by $3.49M in total portfolio value

INVESTMENT

TIME HORIZON10 years

AADI

● Live price

97.56%

Share price

$2.05

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$3.52M

Annual income

$1,168,366.03

Full AADI calculator →

MRK

Merck & Co. Inc.

● Live price

3.25%

Share price

$94.80

Annual div

$3.08

5Y div CAGR

8.2%

Payout ratio

42%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$950.29

Full MRK calculator →

Portfolio growth — AADI vs MRK

📍 AADI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AADI	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AADI + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AADI pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AADI

Annual income on $10K today (after 15% tax)

$8,292.68/yr

After 10yr DRIP, annual income (after tax)

$993,111.13/yr

MRK

Annual income on $10K today (after 15% tax)

$276.16/yr

After 10yr DRIP, annual income (after tax)

$807.75/yr

At 15% tax rate, AADI beats the other by $992,303.38/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AADI + MRK for your $10,000?

AADI: 50%MRK: 50%

100% MRK50/50100% AADI

Portfolio after 10yr

$1.78M

Annual income

$584,658.16/yr

Blended yield

32.89%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

AADI

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$1.63

-20.5% upside vs current

Range: $1.50 — $1.75

Altman Z

1.2

Piotroski

2/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+35.6% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AADI buys

MRK buys

No recent congressional trades found for AADI or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAADIMRK

Forward yield	97.56% ✓	3.25%
Annual dividend / share	$2.00	$3.08 ✓
Payout ratio	50%	42% ✓
1-year div growth	0%	5.5% ✓
5-year div CAGR	0%	8.2% ✓
Portfolio after 10y	$3.52M	$30.7K ✓
Annual income after 10y	$1,168,366.03 ✓	$950.29
Total dividends collected	$3.14M	$6.1K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Buy	Buy
Analyst price target	$1.63	$128.54 ✓

Year-by-year: AADI vs MRK ($10,000, DRIP)

Year	AADI Portfolio	AADI Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$20,456	$9,756.10	$11,192	$351.54	+$9.3K → AADI
2	$40,540	$18,651.56	$12,524	$392.70	+$28.0K → AADI
3	$77,923	$34,545.21	$14,015	$438.65	+$63.9K → AADI
4	$145,434	$62,056.61	$15,682	$489.96	+$129.8K → AADI
5	$263,859	$108,244.60	$17,547	$547.23	+$246.3K → AADI
6	$465,868	$183,539.14	$19,632	$611.16	+$446.2K → AADI
7	$801,335	$302,856.10	$21,963	$682.53	+$779.4K → AADI
8	$1,344,288	$486,859.57	$24,571	$762.18	+$1.32M → AADI
9	$2,201,693	$763,305.13	$27,486	$851.08	+$2.17M → AADI
10	$3,524,178	$1,168,366.03	$30,745	$950.29	+$3.49M → AADI

AADI vs MRK: Complete Analysis 2026

AADI — Stock

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Full AADI Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →

📬

Get this AADI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AADI vs SCHD AADI vs JEPI AADI vs O AADI vs KO AADI vs MAIN AADI vs JNJ AADI vs ABBV AADI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.